The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay

Mark A Frye, Lori L. Altshuler, Martin P. Szuba, Nancy Nowlin Finch, Jim Mintz

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background: This retrospective study was conducted to evaluate the relationship between the mood-stabilizing agents lithium, carbamazepine, and divalproex sodium and time course of drug response as measured by length of hospital stay. Method: Seventy-eight patients were evaluated. Discharge date and length of hospitalization were obtained by review of the dictated discharge summary by investigators who were blind to medication status. Drug choice, including blood levels, was then identified as well as any adjunctive treatment. Statistical evaluation (SAS software) of time to improvement was conducted using nonparametric survival models. Possible confounding variables were assessed by parametric survival regression models and proportional hazards models. Results: The individual survival curves of four major antimanic treatment groups revealed a significant difference by the second week of hospitalization in the divalproex sodium and the lithium/carbamazepine combination groups as compared with the lithium or carbamazepine groups (χ2 = 13.83, df= 3, p = .003). The mean ± SD length of stay was approximately 40% shorter for the divalproex sodium (10.2 ± 2.0 days) and the lithium/carbamazepine combination (11.7 ± 2.1 days) groups compared with the lithium alone (17.6 ± 1.0 days) and the carbamazepine alone (18.1 ± 3.0 days) groups. Regression analysis of possible confounding variables including adjunctive treatment (benzodiazepines and neuroleptics), severity of illness (number of years ill and previous hospitalizations), and discharge date revealed no statistically significant effect. Conclusion: Shortcomings of our study include those inherent in the design of a nonrandomized, small naturalistic study and retrospective chart review. Our study does, however, suggest different drug response rates for the treatment of classic and dysphoric mania and warrants further controlled investigation.

Original languageEnglish (US)
Pages (from-to)17-21
Number of pages5
JournalJournal of Clinical Psychiatry
Volume57
Issue number1
StatePublished - Jan 1996
Externally publishedYes

Fingerprint

Antimanic Agents
Carbamazepine
Bipolar Disorder
Lithium
Length of Stay
Valproic Acid
Hospitalization
Confounding Factors (Epidemiology)
Survival
Retrospective Studies
Pharmaceutical Preparations
Therapeutics
Excipients
Benzodiazepines
Proportional Hazards Models
Antipsychotic Agents
Software
Regression Analysis
Research Personnel

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay. / Frye, Mark A; Altshuler, Lori L.; Szuba, Martin P.; Finch, Nancy Nowlin; Mintz, Jim.

In: Journal of Clinical Psychiatry, Vol. 57, No. 1, 01.1996, p. 17-21.

Research output: Contribution to journalArticle

Frye, Mark A ; Altshuler, Lori L. ; Szuba, Martin P. ; Finch, Nancy Nowlin ; Mintz, Jim. / The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay. In: Journal of Clinical Psychiatry. 1996 ; Vol. 57, No. 1. pp. 17-21.
@article{c0e26ecdc4be4afeb0f031bfa6de483b,
title = "The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay",
abstract = "Background: This retrospective study was conducted to evaluate the relationship between the mood-stabilizing agents lithium, carbamazepine, and divalproex sodium and time course of drug response as measured by length of hospital stay. Method: Seventy-eight patients were evaluated. Discharge date and length of hospitalization were obtained by review of the dictated discharge summary by investigators who were blind to medication status. Drug choice, including blood levels, was then identified as well as any adjunctive treatment. Statistical evaluation (SAS software) of time to improvement was conducted using nonparametric survival models. Possible confounding variables were assessed by parametric survival regression models and proportional hazards models. Results: The individual survival curves of four major antimanic treatment groups revealed a significant difference by the second week of hospitalization in the divalproex sodium and the lithium/carbamazepine combination groups as compared with the lithium or carbamazepine groups (χ2 = 13.83, df= 3, p = .003). The mean ± SD length of stay was approximately 40{\%} shorter for the divalproex sodium (10.2 ± 2.0 days) and the lithium/carbamazepine combination (11.7 ± 2.1 days) groups compared with the lithium alone (17.6 ± 1.0 days) and the carbamazepine alone (18.1 ± 3.0 days) groups. Regression analysis of possible confounding variables including adjunctive treatment (benzodiazepines and neuroleptics), severity of illness (number of years ill and previous hospitalizations), and discharge date revealed no statistically significant effect. Conclusion: Shortcomings of our study include those inherent in the design of a nonrandomized, small naturalistic study and retrospective chart review. Our study does, however, suggest different drug response rates for the treatment of classic and dysphoric mania and warrants further controlled investigation.",
author = "Frye, {Mark A} and Altshuler, {Lori L.} and Szuba, {Martin P.} and Finch, {Nancy Nowlin} and Jim Mintz",
year = "1996",
month = "1",
language = "English (US)",
volume = "57",
pages = "17--21",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "1",

}

TY - JOUR

T1 - The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay

AU - Frye, Mark A

AU - Altshuler, Lori L.

AU - Szuba, Martin P.

AU - Finch, Nancy Nowlin

AU - Mintz, Jim

PY - 1996/1

Y1 - 1996/1

N2 - Background: This retrospective study was conducted to evaluate the relationship between the mood-stabilizing agents lithium, carbamazepine, and divalproex sodium and time course of drug response as measured by length of hospital stay. Method: Seventy-eight patients were evaluated. Discharge date and length of hospitalization were obtained by review of the dictated discharge summary by investigators who were blind to medication status. Drug choice, including blood levels, was then identified as well as any adjunctive treatment. Statistical evaluation (SAS software) of time to improvement was conducted using nonparametric survival models. Possible confounding variables were assessed by parametric survival regression models and proportional hazards models. Results: The individual survival curves of four major antimanic treatment groups revealed a significant difference by the second week of hospitalization in the divalproex sodium and the lithium/carbamazepine combination groups as compared with the lithium or carbamazepine groups (χ2 = 13.83, df= 3, p = .003). The mean ± SD length of stay was approximately 40% shorter for the divalproex sodium (10.2 ± 2.0 days) and the lithium/carbamazepine combination (11.7 ± 2.1 days) groups compared with the lithium alone (17.6 ± 1.0 days) and the carbamazepine alone (18.1 ± 3.0 days) groups. Regression analysis of possible confounding variables including adjunctive treatment (benzodiazepines and neuroleptics), severity of illness (number of years ill and previous hospitalizations), and discharge date revealed no statistically significant effect. Conclusion: Shortcomings of our study include those inherent in the design of a nonrandomized, small naturalistic study and retrospective chart review. Our study does, however, suggest different drug response rates for the treatment of classic and dysphoric mania and warrants further controlled investigation.

AB - Background: This retrospective study was conducted to evaluate the relationship between the mood-stabilizing agents lithium, carbamazepine, and divalproex sodium and time course of drug response as measured by length of hospital stay. Method: Seventy-eight patients were evaluated. Discharge date and length of hospitalization were obtained by review of the dictated discharge summary by investigators who were blind to medication status. Drug choice, including blood levels, was then identified as well as any adjunctive treatment. Statistical evaluation (SAS software) of time to improvement was conducted using nonparametric survival models. Possible confounding variables were assessed by parametric survival regression models and proportional hazards models. Results: The individual survival curves of four major antimanic treatment groups revealed a significant difference by the second week of hospitalization in the divalproex sodium and the lithium/carbamazepine combination groups as compared with the lithium or carbamazepine groups (χ2 = 13.83, df= 3, p = .003). The mean ± SD length of stay was approximately 40% shorter for the divalproex sodium (10.2 ± 2.0 days) and the lithium/carbamazepine combination (11.7 ± 2.1 days) groups compared with the lithium alone (17.6 ± 1.0 days) and the carbamazepine alone (18.1 ± 3.0 days) groups. Regression analysis of possible confounding variables including adjunctive treatment (benzodiazepines and neuroleptics), severity of illness (number of years ill and previous hospitalizations), and discharge date revealed no statistically significant effect. Conclusion: Shortcomings of our study include those inherent in the design of a nonrandomized, small naturalistic study and retrospective chart review. Our study does, however, suggest different drug response rates for the treatment of classic and dysphoric mania and warrants further controlled investigation.

UR - http://www.scopus.com/inward/record.url?scp=0030071272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030071272&partnerID=8YFLogxK

M3 - Article

C2 - 8543542

AN - SCOPUS:0030071272

VL - 57

SP - 17

EP - 21

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 1

ER -